Urinary tract infection

Wondershare Filmora Unveils Innovative Cinematic Editing Solutions in V13.3.0 Update.

Retrieved on: 
Thursday, April 18, 2024
Creativity, Light, UI, Filter, UX, Urinary tract infection, Food

VANCOUVER, BC, April 18, 2024 /PRNewswire/ -- Wondershare, a leading provider of AI-powered creativity solutions, is pleased to announce the latest version of its flagship video editing software, Filmora 13.

Key Points: 
  • VANCOUVER, BC, April 18, 2024 /PRNewswire/ -- Wondershare, a leading provider of AI-powered creativity solutions, is pleased to announce the latest version of its flagship video editing software, Filmora 13.
  • Version 13.3 introduces key UI and UX updates, ensuring a more intuitive editing process.
  • Additionally, Filmora has provided new and improved intelligent colour grading options for users of all skill levels, adding hundreds of Filters and LUTs, including new options for LOG footage.
  • Filmora V13.3's intuitive interface, enhanced color grading, and myriad new filters add to the video editing software's already impressive toolkit.

Wondershare Filmora Unveils Innovative Cinematic Editing Solutions in V13.3.0 Update.

Retrieved on: 
Thursday, April 18, 2024
Creativity, Light, UI, Filter, UX, Urinary tract infection, Food

VANCOUVER, BC, April 18, 2024 /PRNewswire/ -- Wondershare, a leading provider of AI-powered creativity solutions, is pleased to announce the latest version of its flagship video editing software, Filmora 13.

Key Points: 
  • VANCOUVER, BC, April 18, 2024 /PRNewswire/ -- Wondershare, a leading provider of AI-powered creativity solutions, is pleased to announce the latest version of its flagship video editing software, Filmora 13.
  • Version 13.3 introduces key UI and UX updates, ensuring a more intuitive editing process.
  • Additionally, Filmora has provided new and improved intelligent colour grading options for users of all skill levels, adding hundreds of Filters and LUTs, including new options for LOG footage.
  • Filmora V13.3's intuitive interface, enhanced color grading, and myriad new filters add to the video editing software's already impressive toolkit.

Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1)

Retrieved on: 
Thursday, April 18, 2024
FDA, Risk, Social services, Urinary tract infection, Health Canada, Infant, Deliberation, European, Access, Physician, The Committee, Committee, Hospital, Parent, Sanofi, Infection, RSV, Birth control

TORONTO, April 18, 2024 /CNW/ - Quebec's National Institute of Excellence in Health and Social Services (INESSS) recommends BEYFORTUS® to be used for the prevention of RSV lower respiratory tract disease (LRTD) in all neonates and infants aged 8 months and younger.

Key Points: 
  • TORONTO, April 18, 2024 /CNW/ - Quebec's National Institute of Excellence in Health and Social Services (INESSS) recommends BEYFORTUS® to be used for the prevention of RSV lower respiratory tract disease (LRTD) in all neonates and infants aged 8 months and younger.
  • I believe every baby deserves to be protected against RSV and this recommendation for BEYFORTUS® marks an important milestone towards achieving that goal in Quebec.
  • Now is the time to protect all infants against this devastating illness."
  • Sanofi is working with Quebec provincial authorities to make BEYFORTUS® available to a broad cohort of infants for the 2024-25 RSV season.

ARTISTS VS. BIG OIL EXHIBITION BRINGS COMMUNITIES TOGETHER TO RAISE MILLIONS FOR THE CAMPAIGN FOR A SAFE AND HEALTHY CALIFORNIA, WORKING TO "KEEP THE LAW" PROTECTING NEIGHBORHOODS FROM TOXIC DRILLING

Retrieved on: 
Thursday, April 11, 2024
Minter, Big Oil, Health, Schmidt Family Foundation, Legislature, Eric, Goliath, Urinary tract infection, Campaign, Christie's, Soil, Natural Resources, Creativity, Asthma, Community, Social justice

LOS ANGELES, April 11, 2024 /PRNewswire/ -- On Tuesday, April 9th, renowned artists joined with environmental justice advocates and frontline community members to release a new exhibit supporting the Campaign for a Safe and Healthy California in their David vs. Goliath fight against Big Oil to protect neighborhoods from toxic oil drilling.

Key Points: 
  • "The days of Big Oil operating toxic drilling sites with impunity–literally in our backyards where children play–are over.
  • "It's vital for Federated Indians of Graton Rancheria to be part of this effort to protect California neighborhoods from toxic oil drilling.
  • "Grassroots people-power, combined with artists' support and creativity, provides the momentum needed to uphold the law that protects California communities from toxic oil drilling.
  • Ad Paid for by Campaign for a Safe and Healthy California, sponsored by nonprofit environmental and health organizations.

CINELIVE Chooses Sony Electronics' Production Technologies for Its New 4K HDR Cinematic Broadcast Truck

Retrieved on: 
Wednesday, April 10, 2024
Corporation, Sony, Urinary tract infection, Electronics, HDR, SMPTE, IMAG, OB, Creativity, NAB, Entertainment, Television

PARAMUS, N.J., April 10, 2024 /PRNewswire/ -- CINELIVE, a new outside broadcast (OB) truck experience optimized for live entertainment and corporate events, has debuted a new 53-foot cinematic trailer, incorporating Sony's latest production technologies. The mobile unit supports IMAG and streaming and will be used for large live productions, offering an option to achieve a comprehensive cinematic style while offering a user experience familiar to the broadcast community. 

Key Points: 
  • CINELIVE, an outside broadcast truck for live entertainment & corporate events, is using Sony's production technology
    The CINELIVE truck will feature Sony's latest production technologies, highlighted by solutions that support shallow depth of field including:
    8 x HDC-F5500 wired for 16 cameras; Super 35mm system cameras and related accessories, including a 4K ISO record license, which will be used for cinematic event capture.
  • 4 x FR7 : full frame pan-tilt-zoom cameras with an interchangeable SELC1635G wide-angle lens, stationed in the truck with SMPTE fiber bases.
  • "As the broadcast landscape shifts, we're seeing an overwhelming customer desire to produce live events employing a cinematic look," said Zack Pittman, President, CINELIVE.
  • Sony Electronics' technologies will be on display April 14-17, 2024, in booth C8201 at the National Associations of Broadcasters Show ( NAB ) in Las Vegas, and the CINELIVE truck will be present in booth C8539.

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

Retrieved on: 
Wednesday, April 10, 2024
Phase, Inhalation, Pneumonia, Bronchiolitis, Therapy, Urinary tract infection, Incidence, Lung, Plasma, RSV, Pharmaceutical industry

SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.

Key Points: 
  • SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.
  • This drug is indicated for respiratory syncytial virus-associated lower respiratory infections (pneumonia, bronchiolitis) in children.
  • As mentioned by relevant R&D directors of Kexing Biopharm, the Phase I clinical dose-escalation and bronchoalveolar lavage studies of Kexing Biopharm's Human Interferon α1b Inhalation Solution were completed in October 2023.
  • Human Interferon α1b Inhalation Solution, another significant breakthrough in the antiviral field achieved by Kexing Biopharm, is expected to fill this market void.

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

Retrieved on: 
Wednesday, April 10, 2024
Phase, Inhalation, Pneumonia, Bronchiolitis, Therapy, Urinary tract infection, Incidence, Lung, Plasma, RSV, Pharmaceutical industry

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.
  • This drug is indicated for respiratory syncytial virus-associated lower respiratory infections (pneumonia, bronchiolitis) in children.
  • As mentioned by relevant R&D directors of Kexing Biopharm, the Phase I clinical dose-escalation and bronchoalveolar lavage studies of Kexing Biopharm's Human Interferon α1b Inhalation Solution were completed in October 2023.
  • Human Interferon α1b Inhalation Solution, another significant breakthrough in the antiviral field achieved by Kexing Biopharm, is expected to fill this market void.

ABM RESPIRATORY CARE ANNOUNCES AN EXPANDED INDICATION FOR BIWAZE CLEAR

Retrieved on: 
Wednesday, April 10, 2024
FDA, Health, Atelectasis, OLE, ABM, Urinary tract infection, Patient, Bowel obstruction, Pneumonia, Perioperative, Pharmaceutical industry

EAGAN, Minn., April 9, 2024 /PRNewswire/ -- ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel airway clearance and ventilation solutions, is excited to announce the expanded indication granted to the BiWaze® Clear System.

Key Points: 
  • EAGAN, Minn., April 9, 2024 /PRNewswire/ -- ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel airway clearance and ventilation solutions, is excited to announce the expanded indication granted to the BiWaze® Clear System.
  • BiWaze Clear has now received FDA 510k clearance for use in-line with a ventilator in acute care environments.
  • "The expanded use of BiWaze Clear with ventilators underscores our commitment to continuously enhance patient care and highlights the versatility of our BiWaze platform."
  • This expanded indication further emphasizes ABM Respiratory Care's dedication to improving patient outcomes and advancing respiratory care.

Pubic hair: beyond brazilians, more than manscaping

Retrieved on: 
Wednesday, April 10, 2024
Research, Health, Urinary tract infection, Gas, Vibration, Hair loss, Friction, Pressure, Facial expression, Science, Risk, Perspiration, Observation, Partner (business rank), Bacteria, Pheromone, Human, Woman, Body image, Sensation, Urine, Infection, Skin, Eyebrow, Scalp, Gland, Ammonia, Urea, Animal, Emotion

So, what about pubic hair?

Key Points: 
  • So, what about pubic hair?
  • Let’s talk about sex
    Much of the effort that goes into shaping or removing pubic hair also shapes and defines sexual identities.
  • While the properties of pheromones are not as well established in humans, there’s speculation that pubic hair plays a significant role.
  • Pubic hair grooming has been associated with an increased risk of genital infections but this has also been refuted.

EQS-News: G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Retrieved on: 
Wednesday, April 10, 2024
JAMA, Recreational vehicle, Metabolism, CHDR, Entrepreneurship, Dean (education), Viral, Reproduction, University, Head, Volunteering, MD, Urinary tract infection, Infection, Medical school, Clinical trial, Pharmacokinetics, Southern Illinois University, Division, Virus, CMO, University School, Glycolysis, Pharmaceutical industry

An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.

Key Points: 
  • An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.
  • This study aims to assess the effectiveness of 2-DG in preventing illness from rhinoviruses, reducing infection rates, and easing symptom severity.
  • A total of 128 volunteers will participate, receiving up to four daily intranasal doses of either 2-DG or a placebo.
  • 2-DG is a unique and intriguing therapeutic approach to treating viral infections by blocking the virus’ nutrient access,” commented Ronald Bruce Turner, MD, CMO of G.ST Antivirals.